Fortis Memorial Research Institute and Agilus Diagnostics have started a rapid genomic testing program for acute myeloid leukemia (AML) in India. The initiative delivers test results in three days, helping doctors choose faster, more precise treatments. This shift towards personalized care aims to reduce long hospital stays and potentially improve patient outcomes.
A new collaboration between Fortis Memorial Research Institute and Agilus Diagnostics is changing how doctors in India approach the treatment of acute myeloid leukemia (AML). By utilizing rapid next-generation sequencing, the partnership can now provide detailed genetic reports on leukemia samples within three days. This is a significant development because traditional molecular testing can often take weeks, forcing physicians to begin standard, broad-spectrum chemotherapy before knowing the specific genetic drivers of a patient's cancer.
Impact on AML Treatment and Costs
AML is a complex disease with many different subtypes, each responding differently to various drugs. Identifying specific mutations—such as FLT3, NPM1, or TP53—within 72 hours allows hematologists to select targeted therapies or decide on the best course of action much earlier than before. Beyond the clinical benefit, the program focuses on the broader economics of cancer care. According to the team at Fortis, the high cost of treating leukemia in India is driven largely by prolonged hospital admissions, intensive supportive care, and the management of complications from standard, non-targeted chemotherapy.
By enabling faster and more accurate treatment decisions, the initiative aims to shorten inpatient hospital stays from the standard three to five weeks to a much shorter duration. This shift toward managing more therapy in an outpatient setting could lower the financial burden on families by reducing time spent in intensive care units and decreasing the frequency of treatment-related infections.
National Scaling and Future Monitorables
This rapid genomic program has already processed over 5,000 samples and currently supports more than 80 hematologists across India. For investors and stakeholders in the Indian healthcare sector, this move reflects a broader trend of diagnostic laboratories moving toward higher-value, specialized testing services. As companies like Agilus Diagnostics and hospital chains like Fortis expand their capabilities in molecular oncology, the focus will be on how widely these advanced tests are adopted across regional hospitals and whether the reduced duration of hospital stays leads to higher patient throughput or better long-term survival statistics.
The next important monitorables will be the expansion of this testing model to other cancer types and the ability of diagnostic players to maintain these rapid turnaround times as sample volumes increase. Investors may also track how regulatory focus on personalized medicine and potential insurance coverage for advanced genomic panels evolve, as these factors will determine the long-term growth and adoption of such specialized diagnostic services.